Anti–IL-16 mAb treatment significantly reduced signs of disease in an animal colitis model (trinitrobenzenensulfonic acid (TNBS)-induced), such as weight loss, mucosal ulceration, myeloperoxidase activity (P < 0.001), as well as reduced mucosal levels of IL-1β and tumor necrosis factor-α (TNF-α) (59). Here, IL16 is linked to colitis.